There are 594 resources available
9MO - Amivantamab, lazertinib and bevacizumab in EGFR-mutant advanced NSCLC with acquired resistance to 3rd generation EGFR-TKI: Final results from the phase II ETOP AMAZE-lung trial
Presenter: Ross Soo
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
10MO - Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Early success of the COCOON trial
Presenter: Nicolas Girard
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA2, 9MO and 10MO
Presenter: Julien Mazieres
Session: Mini Oral session 1
Resources:
Slides
Webcast
Current role of chemo- and immunotherapy for pleural mesothelioma
Presenter: Arnaud Scherpereel
Session: Update on the treatment of mesothelioma
Resources:
Slides
Webcast
What have we learnt from MARS 2?
Presenter: Eric Lim
Session: Update on the treatment of mesothelioma
Resources:
Slides
Webcast
What have we learnt from EORTC 1205?
Presenter: Jo Raskin
Session: Update on the treatment of mesothelioma
Resources:
Slides
Webcast
Q&A and discussion
Session: Update on the treatment of mesothelioma
Resources:
Webcast
262MO - Real-world validation of artificial intelligence-defined lung nodule malignancy score (qXR-LNMS) in predicting risk of lung cancer
Presenter: Deniz Koksal
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
11MO - AI-based prediction of long-term survival in NSCLC patients treated with immunotherapy: Insights from the multicentric APOLLO11 study
Presenter: Vanja Miskovic
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
297MO - Patterns of disease progression with durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): Results from ADRIATIC
Presenter: Suresh Senan
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast